Skip to main content

Compare Stocks

Date Range: 

 Taysha Gene TherapiesTCR2 TherapeuticsSutro BiopharmaBlack Diamond TherapeuticsVaxcyte
SymbolNASDAQ:TSHANASDAQ:TCRRNASDAQ:STRONASDAQ:BDTXNASDAQ:PCVX
Price Information
Current Price$20.37$19.29$20.32$27.85$18.67
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.81.61.31.61.7
Analysis Score3.53.52.43.53.5
Community Score4.02.62.42.72.9
Dividend Score0.00.00.00.00.0
Ownership Score0.81.71.71.71.7
Earnings & Valuation Score0.60.00.00.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$43.92$43.29$23.33$51.50$48.00
% Upside from Price Target115.59% upside124.39% upside14.83% upside84.92% upside157.10% upside
Trade Information
Market Cap$770.33 million$735.66 million$937.02 million$1.01 billion$958.80 million
BetaN/A2.130.8N/AN/A
Average Volume85,218505,111509,233414,647371,520
Sales & Book Value
Annual RevenueN/AN/A$42.74 millionN/AN/A
Price / SalesN/AN/A21.92N/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book ValueN/A$6.68 per share$4.24 per share($1.44) per shareN/A
Price / BookN/AN/A4.79N/AN/A
Profitability
Net IncomeN/A$-47,600,000.00$-55,740,000.00$-35,260,000.00$-50,270,000.00
EPSN/A($4.62)($2.43)($16.99)N/A
Trailing P/E Ratio0.00N/AN/AN/A0.00
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A27.60%N/AN/A
Return on Equity (ROE)N/A-35.51%-41.86%-22.28%N/A
Return on Assets (ROA)N/A-34.02%-29.50%-17.91%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A0.10%N/AN/A
Current Ratio24.02%32.38%9.77%29.67%10.12%
Quick Ratio24.02%32.38%9.77%29.66%10.12%
Ownership Information
Institutional Ownership Percentage42.19%82.05%78.80%65.78%74.08%
Insider Ownership PercentageN/A27.99%28.90%N/AN/A
Miscellaneous
Employees381181956958
Shares Outstanding37.82 million38.14 million46.11 million36.16 million51.36 million
Next Earnings Date8/10/2021 (Estimated)5/13/2021 (Estimated)8/5/2021 (Estimated)8/10/2021 (Estimated)8/11/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Vaxcyte (NASDAQ:PCVX) Issues  Earnings ResultsVaxcyte (NASDAQ:PCVX) Issues Earnings Results
americanbankingnews.com - May 12 at 6:28 PM
Vaxcyte (NASDAQ:PCVX) Trading Up 7.5% Following Better-Than-Expected EarningsVaxcyte (NASDAQ:PCVX) Trading Up 7.5% Following Better-Than-Expected Earnings
americanbankingnews.com - May 12 at 11:29 AM
Vaxcyte Reports First Quarter 2021 Financial Results and Provides Business UpdateVaxcyte Reports First Quarter 2021 Financial Results and Provides Business Update
finance.yahoo.com - May 11 at 5:55 PM
Vaxcyte Announces Publication of Preclinical Data Supporting the Potential of VAX-24 for the Prevention of Invasive Pneumococcal DiseaseVaxcyte Announces Publication of Preclinical Data Supporting the Potential of VAX-24 for the Prevention of Invasive Pneumococcal Disease
finance.yahoo.com - May 10 at 9:14 AM
Cantor Fitzgerald Weighs in on Vaxcyte, Inc.s FY2022 Earnings (NASDAQ:PCVX)Cantor Fitzgerald Weighs in on Vaxcyte, Inc.'s FY2022 Earnings (NASDAQ:PCVX)
americanbankingnews.com - May 9 at 3:36 AM
Research Analysts Offer Predictions for Vaxcyte, Inc.s FY2022 Earnings (NASDAQ:PCVX)Research Analysts Offer Predictions for Vaxcyte, Inc.'s FY2022 Earnings (NASDAQ:PCVX)
americanbankingnews.com - May 7 at 11:36 AM
Vaxcyte to Present at BofA Securities 2021 Health Care ConferenceVaxcyte to Present at BofA Securities 2021 Health Care Conference
finance.yahoo.com - May 6 at 7:12 PM
Vaxcyte (NASDAQ:PCVX) Reaches New 52-Week Low at $16.84Vaxcyte (NASDAQ:PCVX) Reaches New 52-Week Low at $16.84
americanbankingnews.com - May 6 at 2:52 PM
Vaxcyte, Inc. (NASDAQ:PCVX) Short Interest Down 21.1% in AprilVaxcyte, Inc. (NASDAQ:PCVX) Short Interest Down 21.1% in April
americanbankingnews.com - May 3 at 4:42 PM
Vaxcyte (NASDAQ:PCVX) Stock Price Down 3%Vaxcyte (NASDAQ:PCVX) Stock Price Down 3%
americanbankingnews.com - April 23 at 11:37 AM
Vaxcyte (NASDAQ:PCVX) Stock Price Up 2.7%Vaxcyte (NASDAQ:PCVX) Stock Price Up 2.7%
americanbankingnews.com - April 20 at 1:58 PM
Vaxcyte (NASDAQ:PCVX) Sets New 1-Year Low at $17.45Vaxcyte (NASDAQ:PCVX) Sets New 1-Year Low at $17.45
americanbankingnews.com - April 19 at 1:58 PM
Vaxcyte, Inc. (NASDAQ:PCVX) Short Interest UpdateVaxcyte, Inc. (NASDAQ:PCVX) Short Interest Update
americanbankingnews.com - April 19 at 12:46 PM
Vaxcyte IncVaxcyte Inc
reuters.com - March 31 at 6:00 AM
Vaxcyte asks chairman Slaoui to step down after GSK harassment claimVaxcyte asks chairman Slaoui to step down after GSK harassment claim
finance.yahoo.com - March 25 at 7:35 AM
UPDATE 1-Vaxcyte asks chairman Slaoui to step down after GSK harassment claimUPDATE 1-Vaxcyte asks chairman Slaoui to step down after GSK harassment claim
finance.yahoo.com - March 25 at 7:35 AM
Sexual harassment claim leads to firing of former Operation Warp Speed chief. Will it impact his other board posts?Sexual harassment claim leads to firing of former Operation Warp Speed chief. Will it impact his other board posts?
bizjournals.com - March 24 at 7:26 PM
Vaxcyte to Report Fourth Quarter and Full Year 2020 Financial Results on March 29, 2021Vaxcyte to Report Fourth Quarter and Full Year 2020 Financial Results on March 29, 2021
feeds.benzinga.com - March 22 at 4:28 PM
We Think Vaxcyte (NASDAQ:PCVX) Can Easily Afford To Drive Business GrowthWe Think Vaxcyte (NASDAQ:PCVX) Can Easily Afford To Drive Business Growth
finance.yahoo.com - March 15 at 2:49 PM
Peninsula vaccine maker lands lease at big Alexandria projectPeninsula vaccine maker lands lease at big Alexandria project
bizjournals.com - January 26 at 6:36 PM
Vaxcyte Announces Publication of Preclinical Proof-of-Concept Data Supporting Potential of VAX-A1, a Novel Conjugate Vaccine Designed to Prevent Group A Strep InfectionsVaxcyte Announces Publication of Preclinical Proof-of-Concept Data Supporting Potential of VAX-A1, a Novel Conjugate Vaccine Designed to Prevent Group A Strep Infections
finance.yahoo.com - January 6 at 2:31 PM
Vaxcyte Promotes Andrew Guggenhime to President and Chief Financial OfficerVaxcyte Promotes Andrew Guggenhime to President and Chief Financial Officer
finance.yahoo.com - December 22 at 1:16 PM
Is PCVX A Good Stock To Buy Now?Is PCVX A Good Stock To Buy Now?
finance.yahoo.com - December 10 at 8:42 PM
U.S. IPO Week Ahead: DoorDash And Airbnb Kick Off The Unicorn Parade In A 6 IPO WeekU.S. IPO Week Ahead: DoorDash And Airbnb Kick Off The Unicorn Parade In A 6 IPO Week
seekingalpha.com - December 6 at 4:14 PM
IPO Calendar: December 7 - 11, 2020IPO Calendar: December 7 - 11, 2020
thestreet.com - December 5 at 11:23 PM
DateCompanyBrokerageAction
4/26/2021Taysha Gene TherapiesChardan CapitalReiterated Rating
4/19/2021Taysha Gene TherapiesMorgan StanleyBoost Price Target
3/1/2021Taysha Gene TherapiesWilliam BlairInitiated Coverage
1/4/2021Taysha Gene TherapiesOppenheimerInitiated Coverage
10/19/2020Taysha Gene TherapiesJefferies Financial GroupInitiated Coverage
10/19/2020Taysha Gene TherapiesThe Goldman Sachs GroupInitiated Coverage
4/11/2021TCR2 TherapeuticsMizuhoReiterated Rating
3/17/2021TCR2 TherapeuticsSVB LeerinkLower Price Target
3/11/2021TCR2 TherapeuticsBMO Capital MarketsLower Price Target
3/11/2021TCR2 TherapeuticsPiper SandlerBoost Price Target
12/14/2020TCR2 TherapeuticsHC WainwrightBoost Price Target
11/30/2020TCR2 TherapeuticsRoth CapitalBoost Price Target
8/12/2020TCR2 TherapeuticsTruist FinancialInitiated Coverage
7/27/2020TCR2 TherapeuticsWedbushBoost Price Target
12/2/2020Sutro BiopharmaStifel NicolausInitiated Coverage
7/16/2020Sutro BiopharmaWells Fargo & CompanyInitiated Coverage
5/12/2020Sutro BiopharmaB. RileyDowngrade
3/16/2020Sutro BiopharmaCowenReiterated Rating
1/13/2020Sutro BiopharmaSunTrust BanksInitiated Coverage
10/7/2019Sutro BiopharmaBTIG ResearchInitiated Coverage
9/5/2019Sutro BiopharmaJMP SecuritiesReiterated Rating
7/18/2019Sutro BiopharmaDeutsche Bank AktiengesellschaftInitiated Coverage
1/19/2021Black Diamond TherapeuticsCanaccord GenuityReiterated Rating
11/24/2020Black Diamond TherapeuticsBerenberg BankInitiated Coverage
2/24/2020Black Diamond TherapeuticsJPMorgan Chase & Co.Initiated Coverage
8/14/2020VaxcyteNeedham & Company LLCReiterated Rating
7/7/2020VaxcyteBank of AmericaInitiated Coverage
7/7/2020VaxcyteCantor FitzgeraldInitiated Coverage
(Data available from 5/12/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.